Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates

Why It Matters

The rebound in product sales demonstrates commercial traction in China’s oncology market, while the expanding late‑stage pipeline positions Ascentage for future revenue diversification beyond its current products.

Key Takeaways

• Product sales rose 90% to $82.1 million in 2025.
• Olverembatinib revenue hit $62.2 million, up 81% YoY.
• Lisaftoclax generated $10.1 million in five months.
• Nine Phase III trials ongoing, four cleared by FDA/EMA.
• Cash balance rose to $353.2 million after IPOs.

Pulse Analysis

Ascentage Pharma’s 2025 financial snapshot reflects a classic biopharma transition: while headline revenue dipped due to the loss of a sizable intellectual‑property stream, product sales surged, underscoring the company’s growing commercial foothold in China. The $82.1 million in product revenue—almost double the prior year—was driven primarily by Olverembatinib’s NRDL expansion and the rapid uptake of Lisaftoclax after its conditional approval. A bolstered cash pile of $353.2 million, funded by a $132.5 million IPO and a $190.1 million follow‑on, gives the firm runway to fund its expanding trial portfolio and marketing push.

The commercial narrative centers on two oncology assets. Olverembatinib, a third‑generation BCR‑ABL1 inhibitor, saw an 81% sales jump to $62.2 million, benefiting from nationwide reimbursement and broader hospital formulary inclusion. Lisaftoclax, the first conditional Bcl‑2 inhibitor in China, posted $10.1 million in just five months, signaling strong market acceptance in chronic lymphocytic leukemia and potential spillover into other hematologic indications. Both drugs face competition from global players, but their NRDL status and differentiated dosing regimens provide a pricing advantage in the cost‑sensitive Chinese market.

Beyond current sales, Ascentage’s pipeline is its long‑term engine. Nine Phase III registrational trials—spanning Ph+ ALL, CML, GIST, MDS, AML, and CLL/SLL—are underway, with four already cleared by the FDA and EMA, de‑risking the path to global approvals. The addition of a PROTAC‑based BTK degrader entering Phase I further diversifies its therapeutic arsenal. Successful readouts could unlock new revenue streams and justify the heightened R&D spend of $162.7 million. Investors will watch upcoming data from the POLARIS and GLORA programs, as well as the company’s push to secure NRDL inclusion for Lisaftoclax in 2026, which could cement Ascentage’s position as a leading Chinese oncology innovator.